A review of FK506: A new immunosuppressant agent for the prevention and rescue of graft rejection

Beck, 1989, Effect of FK506 and cyclosporine on human lymphocyte responses in vitro, 21, 3464 Johansson, 1990, Evidence that the immunosuppressive effect of FK506 and cyclosporine are identical, Transplantation, 50, 1001, 10.1097/00007890-199012000-00021 Markus, 1991, Effects of in vivo treatment with FK506 on natural killer cells in rats, Transplantation, 51, 913, 10.1097/00007890-199104000-00037 Yoshimura, 1989, Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigenactivated suppressor cells, as well as induction of alloreactivity, Transplantation, 47, 351, 10.1097/00007890-198902000-00034 Zeevi, 1990, Functional differentiation of human cytotoxic T lymphocytes in the presence of FK506 and CyA, 22, 106 Grailer, 1990, Inhibition of human T and B cell responses in vitro by cyclosporine A, FK 506, RS61443, and IL-2 toxin: Only RS61443 and IL-2 toxin significantly inhibit the IgG memory response, 120 Todo, 1987, Orthotopic liver transplantation in dogs receiving FK506, 19, 64 Monden, 1990, A potent immunosuppressive effect of FK506 in orthotopic liver transplantation in primates, 2266 Ueda, 1990, Induction of graft acceptance after dog kidney or liver transplantation, 22, 80 Lee, 1990, Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy, 22, 78 Ochiai, 1989, Comparative studies on the immunosuppressive activity of FK506, 15deoxyspergualin, and cyclosporine, 21, 829 Ericzon, 1990, Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey, 22, 72 Markus, 1991, Prevention of graft-versushost disease following allogeneic bone marrow transplantation in rats using FK506, Transplantation, 52, 590, 10.1097/00007890-199110000-00002 Cooper, 1991, Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506, 23, 3238 Honbo, 1987, The oral dosage form of FK506, 19, 17 Venkataramanan, 1990, FK506 kinetics following oral administration, 4 Venkataramanan, 1991, Pharmacokinetics of FK 506 in transplant patients, 23, 2736 Venkataramanan, 1990, Pharmacokinetics of FY-506. Preclinieal and clinical studies, 22, 52 Beysens, 1991, FK 506: Monitoring in plasma or in whole blood?, 23, 2745 Grenier, 1991, A whole blood FK 506 assay for the IMx® Analyzer, 23, 2748 Todo, 1990, Early trials with FK506 as primary treatment in liver transplantation, 22, 13 Todo, 1991, One hundred ten consecutive primary orthotopic liver transplants under FK506 in adults, 23, 1397 Takaya, 1991, Retransplantation of liver: A comparison of FK 506 and cyclosporine-treated patients, 23, 3026 Klintmalm, 1993, U.S. Multi-center FK506 Liver Study Group. Multicenter prospective randomized trial comparing FK506 to cyclosporine after liver transplantation: Primary outcome analysis McDiarmid, 1993, U.S. Multi-center FK506 Liver Study Group: A multi-center prospective randomized trial comparing FK506 to cyclosporine (CyA) after liver transplantation: Comparison of efficacy based on incidence, severity and treatment rejection, 55 1993, A European, multicentre, randomized study to compare the efficacy and safety of FK 506 with that of cyclosporine in patients undergoing primary liver transplantation: Six month results 1993, Use of Prograf (FK506) as rescue therapy for refractory rejection after liver transplantation, 25, 679 Gibbs, 1993, Outcome analysis of FK 506 therapy for acute and chronic rejection, 25, 622 1993, Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection, 25, 635 1993, Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation, 25, 641 Shapiro, 1991, FK 506 in clinical kidney transplantation, 23, 3065 Shapiro, 1993, Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: Preliminary report, 25, 669 1993, Japanese study of FK 506 on kidney transplantation: Results of late phase II study, 25, 649 1991, Japanese study of FK 506 on kidney transplantation: Results of an early phase 11 study, 23, 3071 Vincenti, 1993, Analysis of the incidence and outcome of acute rejection in FK506 treated renal transplant recipients: Results of a concentration controlled trial, 197 Jordan, 1993, FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression, 25, 638 Rocher, 1993, Sequential antibody and FK 506 therapy: The utility ofintensified immunosuppression for refractory rejection in renal allograft recipients, 150 Armitage, 1990, Preliminary experience with FK506 in thoracic transplantation, 143 Armitage, 1992, Clinical trial of FK 506 immunosuppression in adult cardiac transplantation, Ann Thorac Surg, 54, 205, 10.1016/0003-4975(92)91371-F Todo, 1993, Intestinal transplantation in humans under FK 506, 25, 1198 Ricordi, 1991, Human islet allotransplantation under FK 506, 23, 3207 Alejandro, 1991, Combined liver-islet allotransplantation in man under FK506, 23, 789 Masaoka, 1991, Phase It study of FK 506 for allogeneic bone marrow transplantation, 23, 3228 Tzakis, 1991, FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation, 23, 3225 Esquivel, 1993, FK506 therapy after pediatric liver transplantation: comparison with cyclosporine (CyA)-treated pediatric patients and adult FK506-treated patients Tzakis, 1993, Two-year experience with FK 506 in pediatric patients, 25, 619 Backman, 1993, Whole blood and plasma levels of FK506 in liver transplant recipients: Correlation to clinical events and side effects, 155 Neylan, 1993, Adverse events in the comparative dose finding trial of FK506 in primary renal transplantation, 154 Andoh, 1993, FK506 nephrotoxicity is potentiated by sodium depletion in a rat model, 157 Distant, 1993, Long-term renal function after liver transplantation: An analysis of 600 patients on cyclosporine or FK506 immunosuppression, 123 Pirsch, 1993, Renal and metabolic effects of liver transplantation (Tx): Comparison of FK506 to CyA with respect to GFR, hypertension, hyperlipidemia, hyperglycemia and hypergalemia, 153 Porayko, 1993, Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients, 25, 665 McCauley, 1991, The effects of cyclosporine A, cyclosporine G, and FK 506 upon prostaglandin production in renal mesangial cells in culture, 23, 3141 Moutabarrik, 1991, FK 506 mechanism of nephrotoxicity: Stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro, 23, 3133 Esquivel, 1993, Experiences with FK506 conversion therapy in pediatric liver transplantation (OLT), 159 Fung, 1991, Adverse effects associated with the use of FK 506, 23, 3105 Eidelman, 1991, Neurologic complications of FK 506, 23, 3175 Reyes, 1990, Expressive dysphasia possibly related to FK506 in two liver transplant recipients, Transplantation, 50, 1043, 10.1097/00007890-199012000-00028 Tabasco-Minguillan, 1993, Long-term insulin requirement after liver transplantation with FK506 in American Veterans, 25, 677 Reyes, 1991, Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression, 23, 3044